Lifeboat Foundation

When the California two-spot octopus isn’t attempting to bring more eight-legged cephalopods into this world, it prefers to be alone. Known to scientists as Octopus bimaculoides, the alien-like invertebrate spends most of its time hiding from the world or searching for food, asocial males avoiding asocial females until their biological clocks say it’s time to partner up. That is, until they are on MDMA. In a groundbreaking study released Thursday, researchers describe how octopuses on the drug act similarly to a socially anxious human on MDMA: They open up.

Gül Dölen, Ph.D., is an assistant professor of neuroscience at Johns Hopkins University and the co-author of the new Current Biology paper. She tells Inverse that when octopuses are on MDMA, it’s like watching “an eight-armed hug.”

“They were very loose,” Dölen says. “They just embraced with multiple arms.”

James Peyer has been a scientist, entrepreneur, and advisor to biotechs and pharma companies, always with a specialization for developing new classes of therapeutics. James founded Apollo to support biotech entrepreneurs strategically, scientifically, and financially as they create the next generation of medicines.

James Peyer received his PhD from the University of Texas Southwestern Medical Center in Dallas, where he was a National Science Foundation Fellow and worked on the basic biology of stem cells and improving gene therapies. He founded his first company, Genotyp, at 21 to overhaul hands-on science education in the US. Genotyp’s innovative biotech equipment leasing model and instructor training earned it the approval of the White House and the National Institutes of Health. It became the first biotech company to receive funding through Kickstarter.com. He received a BA with special honors from the University of Chicago, where he studied immunology.

Discoveries in aging biology are ready for acceleration to the clinic, where they can treat age-related disease and extend healthy lifespan.

Continue reading “Interview with Apollo Ventures which funds anti-aging companies” »

All three of these surprising achievements are highlighted in the Goalkeepers 2018 Data Report, written by Bill and Melinda Gates and released on Sept. 18. But the dispatch—an assessment of the progress made so far on the United Nations’ 17 Sustainable Development Goals and done with the help of the University of Washington’s Institute for Health Metrics and Evaluation—is anything but rah-rah. For every encouraging data point, indeed, there is one that alarms. For every promising advance in the global war on poverty and disease is a perilous outcome if we lose focus or steam.

A report from the Bill & Melinda Gates Foundation focuses on four key areas: Health, education, sanitation, and family planning.

Researchers think it could play an important function in devices using IoT and medical applications.

Giving millions of patients already taking statins a new type of drug could slash their heart disease risk even further, research suggests.

Scientists claim pills that are currently under development, called lipoprotein lipase (LPL) enhancers, could prevent thousands of heart attacks.

Continue reading “Give millions of patients already on statins a new type of drug” »

Today, we want to draw your attention to a new study that looks at the role of chronic age-related inflammation and the decline of nerve regeneration.

Inflammaging drives age-related loss of tissue regeneration

Inflammation can be beneficial and serves an important purpose: it spurs regeneration and immune responses while combating pathogens and other invaders. This kind of inflammation tends to be short-lived and localized to an area of injury. However, there is another form of inflammation, a chronic, smouldering kind that accompanies aging: this is often called inflammaging.

Surging productivity and the general rise in incomes it brings would be welcome, of course, but that isn’t sufficient. The same questions being raised about the advance of robotics in the workplace apply to machine learning. While new jobs would be created, many existing jobs — from doctors and financial advisers to translators and call-center operators — are susceptible to displacement or much-reduced roles. No economic law guarantees that productivity growth benefits everyone equally. Unless we thoughtfully manage the transition, some people, even a majority, are vulnerable to being left behind even as others reap billions.

Whether it’s for the better and for the many is up to human intelligence.

Recently, there has been an explosion of interest in applying artificial intelligence (AI) to medicine. Whether explicitly or implicitly, much of this interest has centered on using AI to automate decision-making tasks that are currently done by physicians. This includes two seminal papers in the Journal of the American Medical Association demonstrating that AI-based algorithms have similar or higher accuracy than physicians: one in diagnostic assessment of metastatic breast cancer compared to pathologists and the other in detecting diabetic retinopathy compared to ophthalmologists.

While promising, these applications of AI in medicine raise a number of novel regulatory and policy issues around efficacy, safety, health workforce, and payment. They have also triggered concerns from the medical and patient communities about AI replacing doctors. And, except in narrow domains of practice, general AI systems may fall far short of the hype.

We posit that the applications of AI to “augment” physicians may be more realistic and broader reaching than those that portend to replace existing health care services. In particular, with the right support from policy makers, physicians, patients, and the technology community, we see opportunities for AI to be a solution for—rather than a contributor to—burnout among physicians and achieving the quadruple aim of improving health, enhancing the experience of care, reducing cost, and attaining joy in work for health professionals.

The world’s largest genetic study of hypertension finds that the number of genetic loci involved is three times larger than previously thought.